Mar 18, 2021 8:00 am EDT Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
Mar 17, 2021 8:00 am EDT Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
Jan 26, 2021 7:30 am EST Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
Jan 6, 2021 8:00 am EST Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event
Dec 29, 2020 7:00 am EST Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
Dec 16, 2020 7:00 am EST Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Dec 3, 2020 7:00 am EST Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End